Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469251 | 0.88 | LMNA (0.33) | LMNA | |
| SCHEMBL461504 | 0.87 | LARS1 (0.39) | MAPTSMN1; SMN2HPGDLARS1KDM4E | |
| SCHEMBL13073614 | 0.85 | TP53 (0.33) | LMNAHPGDCNR2LARS1KDM4E | |
| SCHEMBL13074078 | 0.85 | TP53 (0.33) | LMNAHPGDCNR2LARS1KDM4E | |
| SCHEMBL13073748 | 0.85 | TP53 (0.33) | LMNAHPGDCNR2LARS1KDM4E | |
| SCHEMBL15075004 | 0.82 | ALDH1A1 (0.37) | SMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL16706966 | 0.80 | TP53 (0.35) | HPGDLARS1KDM4EALDH1A1 | |
| SCHEMBL5019552 | 0.80 | TP53 (0.35) | HPGDLARS1KDM4EALDH1A1 | |
| SCHEMBL16706967 | 0.80 | TP53 (0.35) | HPGDLARS1KDM4EALDH1A1 | |
| SCHEMBL13073689 | 0.80 | PLA2G4B (0.32) | LARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| EP-3251678-A1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Anacor Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9751898-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2613788-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012033858-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | MAPT 2926/4885SMN1; SMN2 4062/4885LMNA 3088/4885 |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | MAPT 2926/4885SMN1; SMN2 4062/4885LMNA 3088/4885 |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | MAPT 2926/4885SMN1; SMN2 4062/4885LMNA 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.